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Mosaic strainsomplete VZV genomic sequences resolves wild-type strains into 5 genotypes (E1,
E2, J, M1, and M2). Complete sequences for M3 and M4 strains are unavailable, but targeted analyses of
representative strains suggest they are stable, circulating VZV genotypes. Sequence analysis of VZV isolates
identiﬁed both shared and speciﬁc markers for every genotype and validated a uniﬁed VZV genotyping
strategy. Despite high genotype diversity no evidence for intra-genotypic recombination was observed. Five
of seven VZV genotypes were reliably discriminated using only four single nucleotide polymorphisms (SNP)
present in ORF22, and the E1 and E2 genotypes were resolved using SNP located in ORF21, ORF22 or ORF50.
Sequence analysis of 342 clinical varicella and zoster specimens from 18 European countries identiﬁed the
following distribution of VZV genotypes: E1, 221 (65%); E2, 87 (25%); M1, 20 (6%); M2, 3 (1%); M4, 11 (3%). No
M3 or J strains were observed.
Published by Elsevier Inc.Introduction
Varicella-zoster virus (VZV) is a highly contagious humanpathogen
that causes varicella (chickenpox) onprimary infection, duringwhich a
lifelong latent infection is established (Arvin, 1996). Latent virus can
reactivate, usually later in life, to cause zoster (shingles), a painful rash
illness. VZV can be transmitted to susceptible persons from either
disease condition, although zoster carries a signiﬁcantly lower risk ofose of the authors and do not
nc.transmission; varicella cases transmitted from zoster patients may
reintroduce strains that circulated decades earlier, which probably
contributes to the unusually high conservation of the VZV genome. For
reasons that remain unclear the epidemiology of primary VZV
infection varies geographically; in temperate climates, VZV infects
N90% of children during the ﬁrst decade of life, whereas in tropical
countries primary infection is oftendelayeduntil adulthood (Lee,1998;
Lolekha et al., 2001). Several studies have demonstrated a distinctive
geographic distribution of the major VZV genotypes aligning with
temperate versus tropical regions of the globe (Barett-Muir et al., 2003;
Dayan et al., 2004; Lolekha et al., 2001; Loparev et al., 2007a; Quinlivan
et al., 2002;Waganaar et al., 2003). The regional dominance of speciﬁc
genotypes might have been established by climate and/or other
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naïve populations through immigration or travel. Modern genotyping
strategies may help to resolve these questions. Our approach has
established the regions in which various VZV genotypes predominate,
and these data, combined with historical human migration patterns,
identiﬁed the likeliest points of origin for these genotypes. Thus far
geographic dominance has been observed for E1 and E2 (Europe), M1
(Africa) and J (Japan) genotypes. (Loparev et al., 2004, 2007b; Muir et
al., 2004; Sergeev et al., 2006). The dominance of E genotype strains in
North America and Australia was likely established during European
colonization in the 16th and 17th centuries. Relatively recent changes
in immigration and/or international travel patterns for certain
geographic regions (notably Europe, Australia, and the United States)
are now characterized by co-circulation of a variety of VZV genotypes.
These countries are potential “melting pots” for VZV evolution due to
the enhanced opportunity for dual infection followed by inter-strain
recombination (Koskiniemi et al., 2007; Loparev et al., 2007a, 2004;
Norberg et al., 2006; Quinlivan et al., 2002; Sengupta et al., 2007).
Earlier studies indicate that as many as seven distinct VZV
genotypes are currently circulating, which we designate as E1, E2, J,
M1, M2, M3, and M4 (Loparev et al., 2007a, 2007b, 2004; Sauerbrei et
al., 2004; Sergeev et al., 2006). At least 5 of these same genotypes have
also been detected using other approaches, although different
nomenclatures are applied by each group of investigators (Barrett-
Muir et al., 2003; Campsall et al., 2004; Carr et al., 2004; Muir et al.,
2004; Parker et al., 2006; Peters et al., 2006; Wagenaar et al., 2003).
These studies have consistently observed distinctive geographic
distributions of VZV genotypes. We recently published a two-
amplicon method (Loparev et al., 2007b) that identiﬁes all of the
phylogenetic groups identiﬁed by every method, and veriﬁes the
presence of 5 conﬁrmed and 2 provisional genotypes M3 (Sergeev et
al., 2006) andM4 (Loparev et al., 2007a). Essentially, we identiﬁed SNP
that discriminate E1-genotype from E2 in ORF21, ORF22 [region 2],
and ORF50. Analysis of SNP in any one of these regions is sufﬁcient to
discriminate E1 strains from other European strains. The combination
of ORF22 [region 1]-based genotyping (Loparev et al., 2004) with
analysis of any one of the E1-discriminating SNP thus permits the
identiﬁcation of every described VZV genotype.
Two additional positions in ORF38 (69349) and ORF54 (95241),
originally used to conﬁrm Oka vaccine adverse events, also provide
useful information for genotyping. These two markers are not Oka
vaccine-speciﬁc, but serve rather to distinguish some J, M1, M2, and
M4 strains from other genotypes. A subset of J genotype isolates (e.g.,
pOka, which was the source virus for Oka vaccine) contain a PstI
restriction site in ORF38, and the ORF54 sequence includes a BglI
restriction site common to J, M1,M2, andM4 strains. The identiﬁcation
of SNP by using restriction enzyme hydrolysis has been supplanted by
amplicon sequencing, but it remains convenient to refer to these
markers by their restriction enzyme speciﬁcities. In addition to the J
strains common in Japan, Australia, and some east Asian countries
(Loparev et al., 2007a, 2007b, 2004; Sauerbrei et al., 2004; Sergeev et
al., 2006), Bgl+ strains are also commonly isolated in tropical climates
(e.g., equatorial Africa, India, Bangladesh, southern China, Central
America, and northernAustralia). In contrast, Bgl− viruses are common
in temperate climates (Loparev et al., 2007b; Norberg et al., 2006). Two
Pst−Bgl− isolates have also been observed in Australia (Campsall et al.,
2004) and Germany (Sauerbrei and Wutzler, 2007).
Several alternative methods for genotyping VZV strains have been
published, each of which resolves four or ﬁve of the seven genotypes
identiﬁed using the two-amplicon genotypingmethod (ORF22 [region
1] plus either ORF21, ORF22 [region 2] or ORF50). Two-amplicon
sequence analysis is the onlymethod in current use that identiﬁes all of
7 VZV genotypes (Loparev et al., 2007a, 2007b, 2004; Sauerbrei et al.,
2004; Sergeev et al., 2006).
In this report we describe the distribution of VZV genotypes of
clinical isolates obtained from 18 European nations. We observed thatVZV isolates of genotypes E1, E2, M1, M2, and M4 are circulating in
Europe, but did not detect either J or M3 isolates. In addition, we
identify a set of reference SNP, identical in each particular VZV
genotype, that should be useful for monitoring the occurrence of new
genotypes or recombinant viruses. The dominant genotypes observed
in this study were E1 and E2, which occurred in variable proportion in
northern and southern Europe. We also show a close phylogenetic
relationship for E1, E2, and M4 genotypes, the latter of which was
recently described in southern Europe (Spain, France, and Italy).
Results
Identiﬁcation and phylogenetic analysis for new M4 genotype
Phylogenetic analysis of 18 completely sequenced wild-type VZV
strains segregated those strains into 5 distinct genotypes (Fig. 1A).
Based on this analysis, the recently sequenced Russia 1999 strain was
placed into the E1 genotype. The members within each genotype
displayed between 99.90 and 99.97 identity at the nucleotide level,
corresponding to 33 to 47 single base-pair differences. Representatives
of different genotypes had between 140 to 210 single base-pair
differences. Representative E1 andE2 genotypes isolated in Europe and
in North America displayed a high level of internal stability.
Targeted sequence analysis of a short region in ORF22 [region 1],
coupled with analysis of variable SNP in ORF21, ORF22 [region 2] or
ORF50, robustly identiﬁed the same 5 genotypes, and furthermore
differentiated two provisional genotypes (M3 and M4) for which no
complete genome sequences are available.
We performed targeted sequence analysis of 3 representative M4
strains Spain_4242, France_4415, and Italy_4053 in 30 different
genomic regions (Table 1) selected on the basis of SNP variability
with respect to each putative genotype. 90 SNP were identiﬁed in the
ampliﬁed regions, representing about half of the total SNPs identiﬁed
comparing whole genome sequences of E1, E2, M1, M2 and J strains
(Norberg et al., 2006; Peters et al., 2006). The sequence data from the 3
representative M4 strains, in addition to data from an M1 isolate
(Congo_24), was aligned with published sequence data from the 19
completely sequenced strains, and phylogenetic analysis was
performed. The results of that examination are presented in Fig. 1B,
which reveals that the 3 M4 isolates cluster as a distinct genotype. All
6 genotypes were unambiguously separated from one another, with
high bootstrap values (data not shown). The Russia 1999 and
Congo_24 isolates were allocated to E1 and M1 genotypes based on
their respective reference SNP (Fig. 1B, Table 1). These data reinforce
the allocation of strains represented by France 4415, Spain 4242, and
Italy 4053 to a separate genotype, M4.
VZV SNPs useful for strain genotyping
At least two approaches were taken for genotyping VZV: the
analysis of 2 short amplicons (two-amplicon method), or the
identiﬁcation of individual unique SNP in 5–7 amplicons, each of
which identiﬁes a different genotype. To demonstrate proof of
concept, two-amplicon testing was performed in this study analyzing
three different regions containing SNP that differentiate E1 strains
from E2 strains (ORF21, ORF22 [region 2], and ORF50); in actual
practice, only one of those regions would be evaluated in addition to
ORF22 [region 1].
Theﬁrst strategy (the two-ampliconmethod) provides the broadest
range of genotype recognition short of performing whole genome
sequence analysis. The E group (E1+E2), M1, M2, M3, M4, and J
genotypes can be differentiated by analyzing the combination of 4 SNP
located in ORF22 [region 1] (Table 1). The E group viruses can be
differentiated into E1 andE2byexamining variable SNP fromanyoneof
the following positions: 2596, 2643 (ORF3), 5827 (ORF6), 12284
(ORF10), 14390, 14402 (ORF11), 18054 (ORF12), 23294, 23429, 24092
218 V.N. Loparev et al. / Virology 383 (2009) 216–225(ORF16), 25478, 24654 (ORF17), 33725, 33728 (ORF21), 39394, 39530
(ORF22 [region 2]), 68172, 68254 (ORF37), 75103 (ORF40), 78385,
78545 (ORF43), 87841 (ORF50) and 113243 (ORF66) (Table 1). E1, E2
andM4 genotypes are all Bgl− in ORF54, while M1, M2, M3 and J strain
are all Bgl+.Fig. 1. CLUSTALW v1.83 phylogenetic analysis based on the complete VZV genomes (A). Num
marked in bold in each genotype. This phylogenetic analysis included complete sequences
analyses of aligned sequences of variable regions in 26 VZV ORF. The numbers on the con
analysis based on the complete VZV genomes (A). Number of nucleotide substitutions suppo
phylogenetic analysis included complete sequences for the 5 variable regions (R1–5) and th
regions in 26 VZV ORF. The numbers on the connectors indicate the number of nucleotide dThe other approach takes advantage of SNP speciﬁcally associated
with individual genotypes SNPs. We identiﬁed a number of genotype-
speciﬁc SNP in the course of this study.
E1 isolates included the reference strain VZV-Dumas, and 9 other
strains. As shown in Table 1, E1-speciﬁc SNP were located at positionsber of nucleotide substitutions supporting each genotype are shown. Reference strains
for the 5 variable regions (R1–5) and the origin of replication. (B) PAUP phylogenetic
nectors indicate the number of nucleotide differences. CLUSTALW v1.83 phylogenetic
rting each genotype are shown. Reference strains marked in bold in each genotype. This
e origin of replication. (B) PAUP phylogenetic analyses of aligned sequences of variable
ifferences.
Table 1
Analysis of genomic variation using data from multiple VZV open reading frames: a key to the VZV genotype nomenclatures in current usea
n.e.=no equivalent genotype detected. ⁎This is a provisional VZV genotype. No complete reference sequences are currently available. †Markers used to determine phylogenetic tree in
Fig. 1B, in order to permit evaluation of M4 isolates. ‡Markers used to deﬁnitively distinguish M2 and J strains. ¶Markers used for original ORF22-based method (14). §Additional markers
used to perform two-amplicon method (only ORF21 or ORF50 markers are needed, not both).
a Comparison data used all available completely sequenced VZV reference strains and partially sequenced clinical specimens of M4 isolated in Spain, France and Italy.
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(ORF37) and 87841 (ORF50). There are E2-speciﬁc SNP at positions
14402 (ORF11), 68101 (ORF37), and 75103 (ORF40). Four genotype-
speciﬁc SNP were found for the discrimination of M1 strains: 24533,
24656 (ORF17), 64522 (ORF35), and 101464 (ORF60).Genotype M2 is represented in Table 1 by strains DR and VZV-8.
M2-speciﬁc SNPs were identiﬁed at position 11317 in ORF9, and at
positions 51200 and 51840 in ORF28. Our analysis of M4 isolates
demonstrated the consistent presence of genotype-speciﬁc SNPs at
positions 508 (ORF1), 75073 (ORF 40), and 113256 (ORF66).
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18082 (ORF12), 37902, 39263 (ORF22), 51168 (ORF28), 64259 (ORF35),
95601 (ORF54), 98765 (ORF56), and 100151 (ORF58). No J genotype
strains were detected among the isolates analyzed in this study.
Although J strains have been found to be circulating at low levels in the
UK (Sengupta et al., 2007), it should be noted that authors used a
method that is unable to differentiate between M2 and J genotype
based on SNP located at position 685. This is an important consi-
deration for interpreting observations using SNP that differentiate M2
and J strains, since the M2 strains are sometimes isolated in Europe
(Loparev et al., 2007a, 2004; Sengupta et al., 2007). J and M2 strains
sharemutations at positions 685, 789, 790, 791, 6853, 7091 and several
others (Table 1). Since the J-genotype-speciﬁc SNP at position 37902 is
included in theORF22 [region 1] ampliconwe reported previously, that
genotype can be unambiguously identiﬁed using ORF22 [region 1]
alone.
M4-speciﬁc SNP were identiﬁed at positions 508 (ORF1), 75073
(ORF40) and 113256 (ORF 66). M4 is closely related to genotypes E1
and E2 based on phylogenetic analysis (Fig. 1B); these strains have
identity with E2 strains at positions 2596, 2642, 5827, 68254, 78385,
78545 and share SNPs with both E1 and E2 in at least 20 different loci
(Table 1).
Evaluation of the two-amplicon ORF22-based genotyping scheme using
clinical specimens
We used an enhanced two-amplicon genotyping method (ORF22
[region 1] plus E1-speciﬁc SNP in ORF21, ORF22 [region 2] and ORF50)
to genotype wild-type isolates collected in Europe. These data are
presented in Table 2. Overall, 308 (90.1%) isolates were identiﬁed as
either E1 or E2 viruses. There were 221 (65%) E1 and 87 (25%) E2 VZV
strains identiﬁed. In addition there were 20 (6%) M1 isolates, 3 (1%)
M2 isolates, and 11 (3%) M4 isolates found. No J or M3 isolates were
identiﬁed in this study.
Evaluation of the stability of globally circulating VZV genotypes using a
targeted subset of SNP
The stability of 6 of the 7 prospective genotypes was examined for
all 342 VZV isolates collected from Europe by sequencing targeted
regions of the genome in ORF 1, ORF21, ORF22, ORF38, ORF50, andTable 2
Sample collection and genotyping data for clinical samples from Europe using a panel of SN
Country of origin # Isolates E1 E2 M1 M2 M3
Iceland 17 1 15 0 1 0
Finland 28 10 18 0 0 0
Estonia 3 3 0 0 0 0
Lithuania 5 4 1 0 0 0
Latvia 9 8 1 0 0 0
Belarus 15 12 3 0 0 0
Germany 51 20 21 9 1 0
Greece 3 3 0 0 0 0
Russia (Europe) 57 55 2 0 0 0
Poland 4 2 2 0 0 0
Ukraine 6 5 1 0 0 0
Czech Republic 15 7 8 0 0 0
Romania 4 2 2 0 0 0
France 19 12 2 2 1 0
Italy 17 11 4 0 0 0
Spain 31 15 0 9 0 0
Bulgaria 38 34 4 0 0 0
Albania 20 17 3 0 0 0
Total 342 221 87 20 3 0
ORF38 Bgll+ 0 0 20 3 0
ORF54 Pstl− 0 0 0 0 0
ORF62 Small+ 0 0 0 0 0
ORF62 Small+ 0 0 0 0 0ORF54. The speciﬁc SNP evaluated are indicated in the right hand
column of Table 1 by the symbol †. The variability of wild-type isolates
at these 5 loci, which comprise a total of 14 SNP, was compared to the
completely sequenced reference strains Dumas (E1), HJO (E2), CA123
(M1), DR (M2), and P-Oka (J) and with M4 isolates identiﬁed using
multiple SNP analysis. Representative M4 isolates were also evaluated
at these regions. All E1, E2, M1, and M4 strains consistently have the
nucleotide guanine at position 685 (ORF1); all E1, E2, and M4 strains
have identical SNP proﬁles at positions 789, 790, and 791 (ORF1) 6853,
7091 ORF6, 84983 ORF48, 95241 and 95546 (ORF 54). E2, M1, M2, M4
and J strains were identical at positions 14390 (ORF11), 33725, 33728
(ORF21), 68172 ORF37), and 87841 (ORF50). All 308 E1, E2 and M4
strains were PstI+ (ORF38) BglI− (ORF54), and the genotype M1, M2
strains identiﬁed in this study were PstI+BglI+ (Table 2).
Additional evidence indicating stable differences between J and M2
isolates
Only 3 M2 isolates were detected among the viruses we obtained
from Europe; no J isolates were found. We analyzed 4 additional M2
strains (Australia) and 10 wild-type J strains (Japan and Australia) to
evaluate the consistency of SNP that differentiate M2 and J genotype
strains. Altogether, 18 SNP were evaluated that were useful for
discriminating these two genotypes, at positions 6850 (ORF6), 11317
(ORF9), 18082 (ORF12), 23294 (ORF16), 24578, 24654 ORF17), 37902
(ORF22), 51200, 51840 (ORF28), 64259, 64703, 64740 (ORF35), 85041
(ORF48), 95601 (ORF54), 98659, 98825 (ORF56), 99981 and 100151
(ORF58). All 7 M2 strains had SNP proﬁles identical to both fully
sequenced M2 strains (DR and 8) at the loci identiﬁed above, which
are indicated in the right hand column of Table 1 with the symbol ‡.
The 10 J viruses had SNP proﬁles identical to the reference wild-type
strain pOka at the loci identiﬁed above. As such, care must be taken to
discriminate them to avoid mistyping of M2 European isolates as J
strains.
Evaluation of varicella vaccine-associated SNP among European
wild-type VZV isolates
We analyzed the 342 European isolates for their SNP proﬁles at loci
that are used to discriminate Oka varicella vaccine fromwild-type VZV
strains. Three vaccine-speciﬁc SNP at positions 106262, 107136, andP in ORF 22 [region 1 and 2], ORF 21, ORF 38, ORF50, and ORF 62
M4 J Clinical Isolate Tissue Culture Varicella Zoster
0 0 0 17 5 12
0 0 28 0 3 25
0 0 0 3 3 0
0 0 0 5 5 0
0 0 0 9 9 0
0 0 15 0 0 15
0 0 41 10 41 10
0 0 3 0 3 0
0 0 57 0 57 0
0 0 0 4 4 0
0 0 6 0 6 0
0 0 15 0 6 5
0 0 4 0 4 0
2 0 0 19 4 15
2 0 17 0 17 0
7 0 31 0 31 0
0 0 38 0 Unk Unk
0 0 20 0 19 1
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ORF54 that are not vaccine-speciﬁc, but help to discriminate vaccine J
genotype from other wild-type genotypes. None of the European VZV
isolates studied here carried any of the vaccine-speciﬁc VZVmarkers in
ORF62, and as such all represented wild-type strains (Loparev et al.,
2007a, 2007b, 2004). Among theEuropean isolates, 319were PstI+BglI−
(E1, E2 andM4), and 23were PstI+BglI+ (M1,M2,M3 and Pst+ J strains).
No PstI−BglI+ (the pOka J genotype carried by the vaccine) strains were
identiﬁed. No BglI−PstI− isolates were identiﬁed in this study.
Discussion
The VZV genome is highly conserved, averaging about one SNP for
every 1000 bp of sequence (Loparev et al., 2004; Norberg et al., 2006;
Peters et al., 2006). Recent studies suggest that recombination has
likely played a role in the emergence of currently circulating
genotypes of VZV (Norberg et al., 2006; Peters et al., 2006; Quinlivan
et al., 2002). These factors complicate strategies both for performing
VZV genotypic analysis and strain surveillance. Despite these
obstacles, extensive study of VZV genetic variation by several groups
and, more recently, the availability of nearly two dozen genomic
sequences for diverse wild-type and vaccine VZV isolates, has
provided persuasive evidence for at least 7 distinct, stably circulating
genotypes of VZV (Faga et al., 2001; Barrett-Muir et al., 2003; Campsall
et al., 2004; Carr et al., 2004; Dayan et al., 2004; Koskiniemi et al.,
2007; Loparev et al., 2007a, 2007b, 2004; Muir et al., 2004; Norberg et
al., 2006; Parker et al., 2006; Peters et al., 2006; Quinlivan et al., 2002;
Sauerbrei and Wutzler, 2007; Schmidt-Chanisit et al., 2007; Sengupta
et al., 2007; Sergeev et al., 2006; Tyler et al., 2007; Wagenaar et al.,
2003). These observations provided the impetus for this study, with
the speciﬁc aim of unifying and expanding on all of the genotyping
strategies currently in use.
M3 genotype virus has been isolated in the US (Sergeev et al.,
2006), but it is not a subject of this study and it will not be discussed
further in this paper.
Five groups of reference strains with complete genome sequences
(Dumas, HJO, CA123, DR, and pOka) laid the foundation for a general
method of VZV genotyping. In addition, sequence information from
31 amplicons representing 25 open reading frames and 90 individual
SNP was used to demonstrate that the 11 southern European isolates
belonging to the provisional genotype M4 clearly segregate into their
own phylogenetic cluster. Discovery of a new M4 genotype
demonstrates that ORF 22 sequence evaluation is not only useful
for the surveillance of all currently recognized genotypes, but can
also be useful for the discovery of new VZV genotypes.
In addition, examination of sequence variation at 9 reference SNP
in ORF 21, 22, 38, 54, and 62, demonstrated that the characteristic SNP
signatures for each of the 6 genotypes studied here are stably
maintained among circulating VZV strains, indicating their utility as
an epidemiological tool.
Intra-genotypic variation
Excluding varicella vaccine sequences (all derived from the pOka
strain), complete genomic sequences have now been determined for
19 VZV wild-type strains. This includes a complete sequence for the
strain, Russia 1999, reported here — a Dumas-like E1 genotype virus
isolated approximately 3 decades after the Dumas strain was isolated
from a case of varicella in the Netherlands. The two viruses are
strikingly similar, with only 24 single base differences between them
(0.02% variation at the DNA level). These differences included four
mutations at positions 1758, 9488, 59981, and 101425 that have not
been detected in any other isolates of VZV regardless of genotype.
Russia 1999 shared SNP with strains Kel and 32 at position 15870;
with Kel and SD at positions 51920 and 53523; with strain 32 at
positions 74071, 76377 and 92535; with strains 32, Kel and SD atposition 102403; and with Dumas at positions 104898 and 109044.
Similar SNP analysis of complete genomic sequence for four E2
strains and two M2 strains revealed a comparable level of genotype
stability.
Categories of VZV genomic variation
This investigation conﬁrms previous observations (Loparev et al.,
2007b; Norberg et al., 2006) that three types of genomic variation
(excluding repeat regions and ORIs) are observed among VZV strains:
1) genotype-speciﬁc mutations, 2) mutations shared by some but not
all genotypes, and 3) strain-speciﬁc individual mutations. Examples of
genotype-speciﬁc SNP are observed at positions 35725 (E1), 68101
(E2),101464 (M1), and 11317 (M2); of sharedmarkers at positions 625,
789, 790, 791, 2596, and 6850; and of strain-speciﬁc markers at
position 100123, which has thus far been observed only in the E1
strain, BC. Several methods have relied on SNP analysis to resolve VZV
genotypes (Carr et al., 2004; Loparev et al., 2004, 2007b; Muir et al.,
2004; Parker et al., 2006; Sauerbrei et al., 2004). However, one of
those methods (Carr et al., 2004; Muir et al., 2004; Parker et al., 2006)
fails to discriminate between J genotype and M2 and the single-
amplicon ORF22 [region 1] method (Loparev et al., 2004; Sauerbrei et
al., 2004) discerns E1 and E2 genotypes collectively as E group viruses.
The method described by Muir et al. (2004) is also unable to
distinguish between M4 and E2 genotypes, as we recently demon-
strated (Loparev et al., 2007b). It is possible to resolve the limitations
of any of these approaches by adding SNP to the analysis that expand
the capacity to resolve genotypes, as recently employed for the ORF22
[region 1]-based genotyping method (Loparev et al., 2007b). For
example, incorporating a genotype-speciﬁc J marker (e.g., position
37902) and an M2 marker (e.g., position 51200) into the method (Carr
et al., 2004; Barrett-Muir et al., 2003; Parker et al., 2006) would render
it capable of discriminating at least 5 genotypes. Genotype-speciﬁc
SNP could be used exclusively in a method aimed at identifying all of
the recognized genotypes, but this approach would require having at
least 6 speciﬁc SNP for the genotypes examined in this study (a 7th
would be required to identify the provisional genotype M3). This
approach assumes the absolute stability of the selected targets and
would fail to account for minor variability among strains of the same
genotype. Limiting a method to a handful of genotype-speciﬁc SNP
would likely preclude the detection of novel genotypes and cause the
misdiagnosis of genotypes or genome variants formed through
recombination. This limitation was illustrated here with the potential
for misdiagnosing J and M2 genotypes. A more versatile approach
would take advantage of genotype-speciﬁc and markers shared
among subsets of genotypes, the strategy we have generally relied on.
Recombination in VZV
There is a growing body of evidence suggesting that recombination
occurs among wild-type strains of VZV (Loparev et al., 2004; Norberg
et al., 2006; Peters et al., 2006; Sengupta et al., 2007), and that some
VZV genotypes have signatures of recombination events (Norberg et
al., 2006). We initially used the term mosaic to characterize several
closely related phylogenetic groupings of strains that consisted of
variable alternating patchworks of E-genotype and J-genotype genetic
markers (Loparev et al., 2004). Later, complete genome sequences for
M1 (CA123 and Congo 24) and M2 (DR and 8) viruses conﬁrmed this
prediction and, combined with analysis of complete sequence data
from strains of other genotypes, revealed that in fact 3 more recent
VZV genotypes (M3 has not been sufﬁciently characterized) are
probably derived from VZV ancestral genotypes. Initial studies suggest
that M1, E1 and J are the likeliest progenitor genotypes, but a more
deﬁnitive insight into this question awaits complete genomic
sequences for all 7 genotypes. Genotype J and M2 viruses share the
genotypic marker at position 685: M1 and M2 viruses at position
222 V.N. Loparev et al. / Virology 383 (2009) 216–2256850, E2 and M4 viruses at positions 2596, 2643, and 5827, and a
stretch of SNP at positions 789, 790, and 791 differentiate M1, M2, and
J viruses from E1, E2, and M4 viruses. From this perspective, a
genotyping strategy based on ORF22, ORF21 and ORF50 SNPs
differentiated the 5 well-established VZV genotypes, and facilitated
the identiﬁcation of the M3 and M4. At the same time we
demonstrated that the genomic signatures for all 6 of the genotypes
examined here are quite stable, with almost no evidence of multiple
recombination intermediates. Thus, the evolution of the currently
circulating genotypes is likely to have occurred over a rather long
period of time — certainly more than a century, based on the level of
stability among isolates from recent cases of varicella and herpes
zoster.
Characteristics of E2 strains
We observed unexpected irregular SNP in E2 strains propagated in
tissue culture (positions 12284, 12285, and 113243). This is a
potentially important point since, based on the mosaic pattern of E2
strains, multiple recombination points, a close phylogenetic relation-
ship of E2 viruses with E1 and M4 strains can be postulated. At the
same time, E2 viruses share genomic markers with other M and J
viruses, for example at positions 12284, 12285, 24578, and 39394.
Although HJO and related viruses have a mosaic structure, they
were designated as E2 viruses since the ﬁrst representative strains for
this genotypewere identiﬁed in the UK.Moreover, the reference strain
HJO was isolated in Germany (accession number AJ871403). This also
seems consistent with our observation that E2 strains were the second
most abundant genotype in Europe (87/342; 25.4%). In addition, E1
and E2 viruses are the only genotypes that are consistently negative
for the BglI restriction site in ORF54, and approximately two-thirds ofTable 3
Primers for analysis of genomic variations in clinical specimens
ORF Forward Sequence 5′→3″ Position Reverse Sequence
1 v3 aac agt ctt acg att gcc tag a 378–399 v4 agt agt tt
1 vzv1f tca gct ggc ttt tct aag aat tcg 427–450 vzv1r tat ttt tgg
3 v10 acg gct gta ggt caa cat aca 2166–2183 v11 acg ccc g
6 v16 tgt gct gtc gac aaa ggc ct 5656–5675 v17 tcc cta tg
6 v18 tct cgt agt gaa gcg gca aca 6710–6739 v19 tcc ata tg
8 v22 gcc atc tta tga aga ggt gcg t 8660–8681 v23 aga taa t
9 v26 aat ggc atc ttc cga cgg t 11008–11026 v27 tcg gca g
10 v28 tgt gga cgc att tga tga atc 12231–12251 v29 aca gaa g
11 v31 tcg gat gat ttt ccg gga ta 13800–13819 v29 tcg gta ct
11 v33 taa tac gaa ttg ccg cgt cta a 14910–14931 v34 ttg cac ac
12 v38 agc gaa ctt ctc gcg ttt ta 17766–17785 v39 aag tct cc
16 v46 acg gca gaa cgg aat cca ctg 22980–23000 v47 cag tat aa
21 vzv21f taa tga att gag gcg cgg ttt a 33497–33518 vzv21r cac gtg ta
22 ORF22R1f ggg ttt tgt atg agc gtt gg 37837–37856 ORF21R1r ccc ccg a
22 v72 tac gtg gga cga tgc atg ga 39068–39087 v73 tcg aag t
28 v91 cag aag act gtg aca gtg ccc a 50869–50890 v92 acc ctc tc
35 v112 acg tct tcg ctc tct aac gga c 64163–64184 v113 acc ctc tc
37 v117 atc cat gtg tac ggc agc tca 67684–67704 v118 gag tca t
38 PstA ttg aac aat cac gaa ccg tt 69250–69269 PstB cgg gtg a
40 v127 tga tgg cat atc agg cgt acg a 74412–74422 v128 agc agg a
40 v129 tcg gcg gac tac gtc ctg ct 75093–75112 v130 aag tcg g
43 v133 aca ggt caa tgc gaa ccg tgg tgt 78353–78376 v134 tcg gat ct
48 v143 tgg cac gat cgg gat tgg ata gga t 84668–84692 v144 tga tca gg
50 vzv50f cgc acc caa agt gaa cat cat 87736–87756 vzv50r tct cgg at
54 Nla gaa acc cct gca cca tta aa 95109–95128 Fok tcc ctt ca
54 v160 atc tgg gac agt tct gcc gct tg 95275–95295 v161 tga cca g
56/57 v165 tgg gtt tgt gtc cat cgt aaa cgc t 98302–98326 v166 tgg gtc a
58 v167 cgt tct cgt acg tcc atg acc gct a 98613–98634 v168 ttc cgt ac
60 62f tct taa cca cga ttc ccg ata gc 101421–101443 62r gta tat ga
66 V62-12 tgg cgc cat ctc aac atc a 113087–113105 v62-13 agg ttg ctheir genome is identical, including the SNP located in ORF22. E2
viruses are, however, broadly distributed. They are common or
dominant in northern European countries such as Iceland (15/17,
88.2%), Finland (18/28, 64.2%), and Germany (21/51, 41.2%). E2 strains
have also been isolated in the US, Canada, and Australia, and have been
isolated from tropical regions of the globe.
The characteristics of M4 strains
Three European M4 genotype isolates obtained for this study had
complete identity at the 90 SNP we evaluated. These isolates were
acquired separately, that is, they were not obtained from a single
outbreak or nation. Although these strains have a close phylogenetic
relationship with E1 and E2 strains, they are regarded as an imported
genotype based on their low prevalence in Europe and their
association with African immigrants to European countries (Loparev
et al., 2007b). M4 strains have a unique mosaic SNP pattern in ORF22
[region 1] (Sergeev et al., 2006) and can be discriminated from the
other genotypes using that sequence alone.
The distribution of VZV genotypes in Europe
The number of E1 and E2 isolates identiﬁed among 342 European
isolates (90%) was consistent with the strain distribution (80%)
observed in the United Kingdom (Sengupta et al., 2007). A signiﬁcant
fraction of E1 and E2 isolates (38%) were obtained from cases of
zoster, which occurs predominantly in persons over age 50. As such,
these represented older infections and reinforce the viewpoint that
the E genotypes emerged ﬁrst as the predominant genotypes in
Europe. E1 and E2 strains isolated from the 18 European countries
described in this study are essentially identical to those obtained from5′→3″ Position Amplicon size (bp) Reference
c atg tag ttg agt t 548–569 191
tat ccg caa tgt c 911–932 505 (Arvin, 1996;
Carr et al., 2004)
tc cat acg gta aat 2812–2832 666
c gtt agt ggg gtc t 6130–6151 495
g atg gtc ctc cac t 7144–7165 455
tg tgt cgc ctc cga 9201–9221 561
cc ttt tgt gc 11585–11601 593
ac gcg cca aac tt 12831–12850 619
g taa ctt att tcc ggg t 14302–14326 526
g aat taa ccg ga 15499–15518 608
c atg gta ccg gta a 18430–18451 685
t tgg act ggg ccg 23530–23551 571
g ctc caa aaa ac tag g 33976–33999 502
gg tcc gta ata tc 38264–38283 446 (Arvin, 1996;
Carr et al., 2004)
gg aac ccc atc agt 39699–39719 651
c gat aga cct gtg a 51498–51519 650
c gat aga cct gtg a 51498–51519 650
cc ccg tgc atg tct 68377–68397 713
ac cgt att ctg ag 69580–69599 349 (Grose et al., 2004;
LaRussa et al., 1992)
cg tag tcc gcc ga 75093–75112 700
cc gag cgt atc ca 75093–75112 700
g tgt tgg aag ttt gcg ct 78991–79017 664
a gta cgg ata tca gcc gga 85269–85295 627
g tca aat atg tta cga 88227–88250 514 (Arvin, 1996;
Carr et al., 2004)
t gcc cgt tac at 95311–95330 221 (Grose et al., 2004,
LaRussa et al., 1992)
gg ctt gaa tgg aag taa c 95888–95910 635
ga acc gac cca gga 99021–99041 739
c gac ggc att gct t 100231–100252 1639
g gcg tgg gac tat gc 101474–101496 75 (Loparev et al., 2007c)
gc ttt gca gct aga 113549–113569 482
Table 4
Key to wild-type VZV strains used in the complete genome alignment and genotyping studies
VZV strain Genotype ⁎/⁎⁎/⁎⁎⁎ Case type¶ Year of isolation Country of isolation Accession# Reference
Dumas‡ E1/C/A V 1970s Netherlands XO4370 Davidson and Scott, 1986
BC E1/C/A Z 1999 Canada AY548171 Grose et al., 2004
MSP E1/C/A V 1995 US AY548170 Grose et al., 2004
SD E1/C/A N/A 1980 US DQ479953 Peters et al., 2006
KEL E1/C/A Z 2002 US DQ479954 Peters et al., 2006
36 E1/C/A V 1998 Canada DQ479958 Peters et al., 2006
49 E1/C/A V 1999 Canada DQ479959 Peters et al., 2006
32 p5 E1/C/A V 1976 US DQ479961 Peters et al., 2006
Russia E1/C/A Z 1999 Russian Fed. EU154348 This study
NH293 E1/C/A V 2000 US DQ674250 This study
HJO E2/B/D Z 1990s Germany AJ871403
11 E2/B/D Z 1996 Canada DQ479955 Peters et al., 2006
22 E2/B/D Z 1998 Canada DQ479956 Peters et al., 2006
03-500 E2/B/D N/A 2003 Canada DQ479957 Peters et al., 2006
CA123 M1/A/– V 1990s US DQ457052 Norberg et al., 2006
Cng24 M1/A/– V 1996 DRC† This study
DR M2/J/C Z 2000 US DQ452050 Norberg et al., 2006
8 M2/J/C Z 1995 Canada DQ479960 Peters et al., 2006
02-1-40 M3/–/– V 2002 US Sergeev et al., 2006
Sp4242 M4/–/– V 2003 Spain Loparev et al. 2007a
Fr4415 M4/–/– V 2002 France Loparev et al. 2007a
It4053 M4/–/– V 2005 Italy This study
pOka J/J/B V 1970 Japan Gomi et al., 2002
Genotype nomenclature: ⁎Loparev et al., 2004; ⁎⁎Barrett-Muir et al., 2003; ⁎⁎⁎Peters et al., 2006; – indicates no equivalent genotype detected. ¶V=varicella, Z=herpes zoster,
N/A=not available. ‡Bold type indicates reference strain for this genotype. †Democratic Republic of Congo.
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Norberg et al., 2006; Peters et al., 2006). Isolates representing ﬁve
VZV genotypes (E1, E2, M1, M2 and M4) were identiﬁed from cases of
herpes zoster in this survey, indicating that all of these genotypes
have been circulating in Europe for between ﬁve and eight decades.
E1 strains are more common than E2 strains in Europe, North
America, and Australia.
On the basis of limited SNP analysis reported here, E1 and E2
strains are closely related to M4 strains, with the closest similarity
between E2 and M4. Since M4 strains appear to be of African origin
(Loparev et al., 2007b), it would be useful to determine complete
genomic sequence for one or more M4 viruses to clarify the evolution
and natural history of these genotypes. For example, such informa-
tion might provide evidence for the speculation that E2 and M4
viruses may have arisen in remote European colonies through
recombination events. In those environments the recombinant
strains might have effectively out-competed the original local strains
and imported E1 strains, establishing themselves in the population
after importation to Europe. Alternatively, E2 and M4 strains might
have arisen in Europe in countries with E1 and M strains co-
circulating, spreading afterwards to colonies; or recombinant variants
of E2 could have been selected by temperate climates to which
increasing numbers of people migrated from regions with warmer
climates. Earlier studies indicated that VZV genotypes preferentially
distribute based on warm versus cool climates (Loparev et al., 2004).
We noted that M4 strains are more common than E2 strains in
southern Europe.Table 5
Comparison of recently reported genotyping methods for VZV strains
Genotyping method Genotype designation
31-SNP E1 E2 J M1 M2 M3
Multi-SNP (MSNP) C B J A J n.e
ORF22 region 1 (22R1) E E J M1 M2 M3
Whole Genome Canada (WGCan) A D B n.e.† C n.e
Whole Genome CDC (WGCDC) E1 E2 J M1 M2 n.e
⁎Provisional genotypes based on targeted SNP analysis. No complete sequences are available a
this method. ‡ Cannot be determined by this method since complete sequences are unavailAnother important observation in this study was the complete
absence of J strains in Europe. J genotype strains have been reported in
the UK (Parker et al., 2006; Sengupta et al., 2007), but their protocol
would not have distinguished between J and M2 isolates. J genotype
strains do, however, appear to be entering into populations with a
history of Asian immigration, such as western North America and
Australia (Loparev et al., 2004, 2007b, Wagenaar et al., 2003), and J
genotype may be competing with E1 for dominance in Australia
(Loparev et al., 2007b). It appeared initially that J genotype strains
were literally restricted to Japan, but more recently isolates have been
identiﬁed in other Eastern Asian countries (unpublished data) and
Australia (Loparev et al., 2007b), and isolates that were probably J
genotype have been observed in Thailand (Wagenaar et al., 2003). In
this respect, the distribution of wild-type J strains has important
implications for future varicella vaccine adverse event surveillance in
different regions of the globe.
Summary
These data illustrate the relationships between VZV genotypes that
were circulating in Europe prior to the use of Oka varicella vaccine
(genotype J), and may provide insights useful for interpreting events
that could occur following the broad future introduction of the vaccine
virus in regions originally free of J viruses. It also underscores the utility
of this approach toVZVgenotyping for the comprehensive identiﬁcation
of recognized genotypes, the detection of new genotypes, and for VZV
vaccine strain surveillance.Reference
⁎ M4⁎ This report¶
. n.e. Barrett-Muir et al., 2003; Campsall et al., 2004; Carr et al., 2004;
Muir et al., 2004; Quinlivan et al., 2002
M4 Dayan et al., 2004; Loparev et al., 2000a, 2004; Sergeev et al., 2006
.‡ n.e.‡ Peters et al., 2006
.‡ n.e.‡ Norberg et al., 2006; Loparev et al., 2007b
t this time. †CA123 sequence (M1 strain)was published subsequent to the publication of
able. ¶Determined using the two-amplicon method.
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human herpesvirus, with the possible exception of HHV-8. Studies of
VZV genomic diversity have led to the identiﬁcation of multiple, stably
circulating genotypes, to the establishment of the distinctive global
distribution of genotypes, and to the observation that this distribution
is in ﬂux in countries that encourage immigration. In this study, we
also demonstrate that methods used for genotyping the highly
conserved VZV need to strike a reasonable balance between whole
genome sequencing (impractical as a routine laboratory tool) and
targeted sequence analysis. Since all of the herpesviruses have
relatively stable DNA genomes, it is likely that some of the obstacles
overcome for effectively genotyping VZV will be extendable to other
members of the herpesvirus family.
Materials and methods
Patients
342 specimens from 217 cases of varicella and 83 cases of zoster
were collected between 1998 to 2006 from patients seen in local
hospitals in Albania, Belarus, Bulgaria, Czech Republic, Estonia,
Finland, France, Germany, Greece, Iceland, Italy, Latvia, Lithuania,
Poland, Romania, Russian Federation (European region), Spain, and
Ukraine. The origin of several strains was described in a previous
publication (Loparev et al., 2004). Thirty-eight of the isolates had no
available data on clinical presentation. DNA from 67 of the isolates was
obtained from cells infected with VZV recovered fromvesicular swabs.
Molecular epidemiology
VZV DNA positive specimens were placed on Whatman FTA ﬁlters
and stored at room temperature. DNA samples obtained from Iceland,
Estonia, Lithuania, Latvia, Germany, Poland, and Francewere extracted
from 70 μl of cell suspension infected with single passage VZV from
the isolates. Specimens were applied to FTA cards (Whatman, Inc.,
Florham Park, NJ) to inactivate virus, and were shipped to CDC for VZV
genotyping. One 3-mm-diameter punch from FTA cards was prepared
for PCR according to the manufacturer's instructions. In several
instances ﬁlters were washed with Whatman FTA washing reagent
and reused in several PCR reactions.
VZV Oka vaccine virus was discriminated from wild-type viruses
by evaluating the SNP at positions ORF62 (106262, 107252, and
107136) using real-time FRET (ﬂuorescent resonance energy transfer)-
based PCR as previously described (Loparev et al., 2000b, 2007c;
Sauerbrei et al., 2004). We also performed quantitative real-time PCR
with the Minor Groove Binding (MGB) Eclipse probe System for Allelic
Discrimination (Epoch Biosciences, Inc.) to evaluate VZV Oka vaccine-
speciﬁc SNP, including the MspI/NaeI restriction site at position
107252, using an approach similar to that described by Campsall et al.
(2004). Brieﬂy, modiﬁedMGB Eclipse primermixes contained forward
and reverse primers for ampliﬁcation 5′-GCC CAA AAA CAC TTT ATC
CTA C and 5′-GTT GTT GGAGAAGGGTGA;MGBDark Quencher Eclipse
probe Mix — GCC TTT GCC AGC-(FAM) wt probe and (Dark Quencher
CPG) 5′-GAG CCT TTG CCG G-(TET) mutant probe were used for
detection. To ensure adequate DNA to perform multiple (10–20)
ampliﬁcation procedures, only samples with at least 1×106 VZV
genome copies were used for procedures requiring extensive SNP
analysis. The PstI and BglI restriction sites in ORF 38 and 54 were
evaluatedusingﬂuorescent probes as previously described (Dayanet al;
2004). For ORF22 genotyping, the forward and reverse primers (p22R1f
and p22R1r) were designed to amplify a 447-bp fragment (positions
37837 to 38264) that contains 4 SNP capable of resolving most of the
recognized genotypes of VZV (Loparev et al., 2004; Sengupta et al.,
2007). Multi-locus DNA sequence analysis at ORF 1, 3, 6, 8, 9, 10–12, 16,
17, 21, 22, 28, 35, 37, 40, 43, 48, 50, 54–56, 58, 60, 62, 66 was performed
on amplicons produced using the primers listed in Table 3. DNAsequence was determined on an ABI Prism 3100 DNA sequencer
(Perkin-Elmer, Foster City, CA.) using the BigDye terminator method as
previously described (Loparev et al., 2004). All genomic loci refer to the
published sequence for the Dumas strain (GenBank accession
#9625875). The published wild-type genomic strain sequences used
in these analyses are identiﬁed in Table 4. The Russia_1999 strain was
isolated in 1999 from an adult with herpes zoster in the Russian
Federation. The complete sequence for this strain has been deposited in
GenBank (accession number EU154348). For ease of comparison with
other reports in the literature, we have included a key to all
nomenclature systems for VZV in current use (Table 5).
Bioinformatics
The CLUSTALW v1.83 and BioEdit Sequence Alignment Editor for
Windows 95/98/NT/XP www.mbio.ncsu.edu/BioEdit/bioedit.html)
programs were used to analyze all of the complete VZV genomic
sequences currently available, and speciﬁcally to generate sequence
alignments and phylogenetic trees. Each alignment was inspected and
optimized to remove the 5 repeat regions (R1 to R5) and length
variability in the origin of replication. Bayesian posterior probability
inference of phylogeny used MrBayes version 3.1. MrBayes settings for
the best-ﬁt model (GTR+I+G) were selected by hLRT in MrModeltest
2.2. Phylogenetic trees were generated using TREEVIEW. Nucleotide
sequences obtained from targeted sequencing of three M4 isolates
from France, Spain and Italy were analyzed and aligned with the
Sequencher program version 4.6 (Gene Codes Corp., Ann Arbor, MI,
USA). Each alignment was inspected and Genetics Computer Group
Wisconsin Package, version 10.3 (Accelrys, San Diego, CA, US)
phylogenetic analyses were performed by using PAUP version 4.01
(Sinauer Associates, Sunderland,MA, US). All phenogramswere drawn
as unrooted trees.
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